Pfizer extends vesting and performance periods on 2022/2023 long-term equity awards for ~9,000 employees

PFIZER INC

Up to 9,000 active employees eligible, including CEO Bourla, CFO Denton, and other named executives.
2022 and 2023 TSRUs can be extended for 2 years: settlement now Feb 2029 (2022 grants) and Feb 2030 (2023 grants).
2022 and 2023 PSAs can get a 2-year performance period extension, vesting in 2027 and 2028 respectively.
Modifications aim to restore retention value after COVID-related stock price decline reduced award incentive.
Election is voluntary via a forthcoming tender offer; all other award terms remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.